20,929 Shares in BioNTech SE (NASDAQ:BNTX) Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new stake in BioNTech SE (NASDAQ:BNTX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 20,929 shares of the company’s stock, valued at approximately $2,486,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC increased its stake in shares of BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after buying an additional 238 shares during the period. Baader Bank Aktiengesellschaft increased its holdings in BioNTech by 4.2% in the second quarter. Baader Bank Aktiengesellschaft now owns 140,750 shares of the company’s stock valued at $11,258,000 after purchasing an additional 5,650 shares during the period. LA Financiere DE L Echiquier raised its position in BioNTech by 9.5% during the 2nd quarter. LA Financiere DE L Echiquier now owns 234,539 shares of the company’s stock worth $18,848,000 after purchasing an additional 20,427 shares during the last quarter. Slow Capital Inc. grew its position in shares of BioNTech by 12.0% in the 2nd quarter. Slow Capital Inc. now owns 51,080 shares of the company’s stock valued at $4,105,000 after buying an additional 5,467 shares during the last quarter. Finally, Van ECK Associates Corp grew its position in shares of BioNTech by 1.9% in the 2nd quarter. Van ECK Associates Corp now owns 119,901 shares of the company’s stock valued at $9,635,000 after buying an additional 2,192 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $121.72 on Monday. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The stock’s 50 day moving average is $113.91 and its 200-day moving average is $99.60. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $29.18 billion, a price-to-earnings ratio of -57.96 and a beta of 0.22.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The business’s revenue was up 38.9% on a year-over-year basis. Sell-side analysts forecast that BioNTech SE will post -3.72 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and increased their target price for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. BMO Capital Markets reiterated an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. Finally, UBS Group boosted their price objective on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average price target of $138.67.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.